Stock Traders Buy High Volume of Call Options on Valeant Pharmaceuticals Intl (VRX)

Valeant Pharmaceuticals Intl Inc (NYSE:VRX) (TSE:VRX) was the target of unusually large options trading on Wednesday. Stock investors purchased 15,793 call options on the company. This is an increase of approximately 145% compared to the average daily volume of 6,458 call options.

Valeant Pharmaceuticals Intl (VRX) opened at 12.52 on Friday. The stock has a 50 day moving average price of $11.76 and a 200-day moving average price of $13.13. Valeant Pharmaceuticals Intl has a 12-month low of $8.31 and a 12-month high of $32.74. The company’s market capitalization is $4.36 billion.

Valeant Pharmaceuticals Intl (NYSE:VRX) (TSE:VRX) last posted its quarterly earnings data on Tuesday, May 9th. The specialty pharmaceutical company reported $2.80 EPS for the quarter, topping the consensus estimate of $0.87 by $1.93. The firm had revenue of $2.11 billion during the quarter, compared to analyst estimates of $2.17 billion. Valeant Pharmaceuticals Intl had a positive return on equity of 43.81% and a negative net margin of 22.17%. Valeant Pharmaceuticals Intl’s revenue was down 11.1% on a year-over-year basis. During the same period in the prior year, the business posted ($1.08) EPS. Equities analysts predict that Valeant Pharmaceuticals Intl will post $3.89 EPS for the current fiscal year.

In related news, CFO Paul Herendeen purchased 24,000 shares of Valeant Pharmaceuticals Intl stock in a transaction on Tuesday, March 14th. The shares were purchased at an average price of $10.72 per share, for a total transaction of $257,280.00. Following the transaction, the chief financial officer now owns 174,000 shares of the company’s stock, valued at approximately $1,865,280. The purchase was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Schutter Richard U. De purchased 20,000 shares of Valeant Pharmaceuticals Intl stock in a transaction on Thursday, May 11th. The stock was bought at an average price of $13.90 per share, for a total transaction of $278,000.00. Following the transaction, the director now directly owns 70,572 shares in the company, valued at approximately $980,950.80. The disclosure for this purchase can be found here. In the last ninety days, insiders acquired 3,054,000 shares of company stock valued at $33,103,280. Insiders own 16.37% of the company’s stock.

Several large investors have recently bought and sold shares of the company. Gruss & Co. Inc. bought a new stake in Valeant Pharmaceuticals Intl during the first quarter valued at approximately $104,000. Financial Architects Inc raised its stake in Valeant Pharmaceuticals Intl by 18.6% in the first quarter. Financial Architects Inc now owns 9,550 shares of the specialty pharmaceutical company’s stock valued at $105,000 after buying an additional 1,500 shares during the period. Harbor Advisors LLC bought a new stake in Valeant Pharmaceuticals Intl during the first quarter valued at approximately $110,000. WMS Partners LLC bought a new stake in Valeant Pharmaceuticals Intl during the first quarter valued at approximately $116,000. Finally, Brave Asset Management Inc. bought a new stake in Valeant Pharmaceuticals Intl during the first quarter valued at approximately $119,000. Hedge funds and other institutional investors own 64.34% of the company’s stock.

VRX has been the topic of a number of analyst reports. Royal Bank of Canada reduced their price target on Valeant Pharmaceuticals Intl to $21.00 in a research report on Wednesday, March 1st. BMO Capital Markets upped their price target on Valeant Pharmaceuticals Intl to $21.00 in a research report on Wednesday, March 1st. Guggenheim reiterated a “buy” rating and issued a $55.00 price target on shares of Valeant Pharmaceuticals Intl in a research report on Tuesday, February 28th. Jefferies Group LLC reduced their price target on Valeant Pharmaceuticals Intl from $22.00 to $18.00 and set a “buy” rating on the stock in a research report on Wednesday, March 1st. Finally, Stifel Nicolaus reiterated a “buy” rating and issued a $45.00 price target on shares of Valeant Pharmaceuticals Intl in a research report on Wednesday, May 10th. Two analysts have rated the stock with a sell rating, fourteen have assigned a hold rating, four have issued a buy rating and one has issued a strong buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and an average price target of $18.12.

WARNING: “Stock Traders Buy High Volume of Call Options on Valeant Pharmaceuticals Intl (VRX)” was originally published by Mideast Time and is the property of of Mideast Time. If you are viewing this story on another domain, it was stolen and reposted in violation of US and international trademark & copyright legislation. The legal version of this story can be accessed at https://www.mideasttime.com/stock-traders-buy-high-volume-of-call-options-on-valeant-pharmaceuticals-intl-vrx/1768240.html.

About Valeant Pharmaceuticals Intl

Valeant Pharmaceuticals International, Inc is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices).new TradingView.widget({ “height”: 400, “width”: 625, “symbol”: “VRX”, “interval”: “D”, “timezone”: “Etc/UTC”, “theme”: “White”, “style”: “1”, “locale”: “en”, “toolbar_bg”: “#f1f3f6”, “enable_publishing”: false, “hideideas”: true, “referral_id”: “2588”});

Receive News & Ratings for Valeant Pharmaceuticals Intl Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeant Pharmaceuticals Intl Inc and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply

 
© 2006-2017 Mideast Time.